From a clinical perspective, the loss of CD58 has been associated with relapse and immune escape in hematological cancers and thus has broader impact beyond just CAR T cell therapy, as we have outlined here (35–37). Here, CD58 is linked to hematopoietic and lymphoid cell neoplasm.